AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
• The Bon-Ton Stores, Inc. (BONT) Post Smaller Q1 Loss; Reaffirms Outlook
• Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain

Create E-mail Alert Related Categories

Earnings

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?